# reload+after+2024-01-23 20:45:39.798007
address1§1200 Page Mill Road
city§Palo Alto
state§CA
zip§94304
country§United States
phone§650 281 0850
website§https://kodiak.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
fullTimeEmployees§116
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Victor  Perlroth M.D.', 'age': 50, 'title': 'Co-Founder, Chairman, CEO & President', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 1083676, 'exercisedValue': 0, 'unexercisedValue': 2904000}, {'maxAge': 1, 'name': 'Mr. John A. Borgeson CPA, M.B.A.', 'age': 61, 'title': 'Senior VP, CFO & Secretary', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 667521, 'exercisedValue': 0, 'unexercisedValue': 898318}, {'maxAge': 1, 'name': 'Dr. Michael S. Louie Ph.D.', 'title': 'Senior VP of Digital Transformation & Chief Information Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Hong  Liang', 'age': 51, 'title': 'Senior Vice President of Discovery Medicine', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 300709, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Stephen  Raillard Ph.D.', 'title': 'Senior Vice President of Chemical Development & Manufacturing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Almas  Qudrat M.Sc.', 'title': 'Senior Vice President of Quality Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. J. Pablo Velazquez-Martin M.D.', 'title': 'Senior Vice President of Clinical Research & Translational Medicine', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Tracy  Chien', 'title': 'VP & Corporate Controller', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§9
compensationRisk§10
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.004
currency§USD
dateShortInterest§1702598400
forwardEps§-3.15
pegRatio§-0.05
exchange§NGM
quoteType§EQUITY
shortName§Kodiak Sciences Inc
longName§Kodiak Sciences Inc.
firstTradeDateEpochUtc§1538659800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§557800df-7007-3d0a-a42a-afe9fdcb28bd
gmtOffSetMilliseconds§-18000000
targetHighPrice§12.0
targetLowPrice§2.0
targetMeanPrice§4.33
targetMedianPrice§3.0
recommendationMean§3.3
recommendationKey§hold
numberOfAnalystOpinions§6
quickRatio§4.884
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
